![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, November 21, 2021 5:12:46 PM
Atomwise is powered by a drug discovery algorithm that uses a neural network to simulate how different small molecules may bind to a protein. The machine learning technique allows scientists to rapidly simulate the interactions of millions of molecules to determine which have potential in preclinical trials. Because of their convoluted structures and the complex ways they interact, thousands of proteins remain unlinked to any drug treatments. Atomwise’s 250 customers, which include research institutions like Columbia University and pharmaceutical companies like Bayer, are running nearly 800 projects across areas including cancer, clotting disorders and brain diseases. It’s already helped to discover promising drugs for multiple sclerosis and ebola which were successful in animal trials.
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM